Interferons provide an important defense against viral infection as part of the innate immune systems of vertebrates. They provide antiviral functions by stimulating susceptible cells to express interferon-regulated genes, subsets of which show antiviral activities. Three interferon-regulated antiviral pathways have been described previously, including the double-stranded-RNA-dependent protein kinase R (14, 27, 28) , the 2Ј,5Ј-oligoadenylate synthetase/RNase L system (41) , and the Mx protein (2, 18, 30) pathways. Other proteins with potential antiviral activities are ISG20 (11, 12) , ISG15 (22, 29) , promyelocytic leukemia protein (PML) (31) , guanylate binding protein 1 (GBP-1) (1), P56 (17, 20) , and RNA-specific adenosine deaminase 1 (ADAR1) (35, 38) .
The gene that encodes IFP35 (interferon-induced 35-kDa protein), an interferon-induced protein, was first isolated through differential screening of a cDNA library from HeLa cells that were treated with gamma interferon (3) . IFP35 can be induced by alpha/beta-interferon in various cells, including fibroblasts, monocytes/macrophages, and epithelial cells. It can translocate from the cytoplasm to the nucleus upon interferon stimulation (3) . IFP35 contains a unique N-terminal leucine zipper motif, but it lacks the basic domain that is crucial for DNA binding. Its C terminus has two tandem Nmi/IFP35 homology domains (NIDs). IFP35 can homodimerize in vitro and can be stabilized by Nmi (N-Myc-interacting protein) through heterodimerization. It can also interact with CKIP-1 (casein kinase 2-interacting protein-1) (40) and B-ATF (basic leucine zipper transcription factor, ATF-like) (37) . These protein-protein interactions suggest a potential role for IFP35 in apoptosis and other cytokine-signaling pathways.
Foamy viruses (FVs), also known as spumaretroviruses, are complex retroviruses which compose the only genus in the Spumaretrovirinae subfamily of the Retroviridae. These viruses can infect humans and monkeys as well as many other mammals (such as cattle, cats, and horses). Infection leads to lifelong latency in almost all organs, without detectable viral replication. FVs are unique among the retroviruses in certain aspects, such as their forming a separate pol mRNA, having an infectious DNA genome, and encoding two functional promoters, the long terminal repeat (LTR) and the internal promoter. The transactivator protein (Tas) of FV acts as the key regulator of viral replication and gene expression. Tas is a DNA binding protein that can transactivate both the LTR and the internal promoter by specifically binding to transactivationresponsive elements (19, 21) .
Interferons are believed to play a protective role against the lytic replication of prototype FV (PFV) by inhibiting the synthesis of viral proteins and RNAs (33) . Gamma interferon plays an important role in controlling FV replication to nonpathogenic levels in vitro (13). Regad et al. reported that PML could inhibit the replication of PFV by interfering with Tas (31). However, a later study by Meiering and Linial found that the endogenous PML did not play an important role in PFV latency in vitro (25) . The replication of PFV was found to occur in the presence of substantial PML, either in fully permissive cells or during the reactivation of latent PFV. Therefore, there must be some other unknown factors that play more-important roles in inhibiting PFV.
In this study, we provide evidence that IFP35 plays a key role in the interferon-mediated anti-FV response. IFP35 was identified as a novel bovine Tas (BTas)-interacting protein via yeast two-hybrid screening. Overexpression of IFP35 not only can down-regulate the transactivation ability of BTas and Tas but also can efficiently inhibit the replication of bovine FV (BFV) using polyethyleneimine (Sigma) (9) and the following DNA constructs: BFV pLTR-luc, pCMV-IFP35, pCMV-BTas, or pcDNA3.1 (ϩ), with pCMV ␤-gal as the control for transfection efficiency. Cells were harvested 48 h after transfection, and then luciferase assays (Promega) were performed. The transfection efficiency was assessed by determining the ␤-galactosidase activity, which was used to normalize the luciferase activities. Total amounts of DNA were equalized by adding the vector DNA. Subcellular localization. HeLa and 293T cells were grown on coverslips and cotransfected 24 h later with 0.2 g of pcDNA3.1 (ϩ) or pCMV-BTas and 0.5 g of pMyc-IFP35. Forty-eight hours later, cells were fixed in 4% paraformaldehyde and permeabilized with 0.2% Triton X-100. Indirect immunofluorescence was carried out by using the anti-BTas and anti-Myc antibodies and the Texas Redconjugated goat anti-rabbit (Molecular Probes) and fluorescein isothiocyanate (FITC)-conjugated rabbit anti-mouse (Dako) secondary antibodies. Cellular nuclei were stained with 4Ј,6-diamidino-2-phenylindole (DAPI). Fluorescence microscopy was carried out by using an Olympus fluorescence microscope.
FV-activated GFP assay. BHK21 cells were transfected with the green fluorescent protein (GFP) gene that was driven by the BFV LTR for establishing an indicator cell line named BICL. BICL cells were plated in six-well plates at a density of 2 ϫ IFP35 siRNA. Three small interfering RNA (siRNA) oligonucleotides derived from the human IFP35 RNA sequence were designed to contain a sense strand of 21 nucleotides of the IFP35 gene. The three sequences were cloned into the pBS/U6 vector (a gift from Yang Shi) by following the manufacturer's instructions and confirmed by sequencing. One sequence from the three sequences was selected for stable transfection (oligonucleotide 1, GGAGATCCAGAAGGCT GAGAAAGCTTTCTCAGCCTTCTGGATCTCCCTTTTTG, and oligonucleotide 2, AATTCAAAAAGGGAGATCCAGAAGGCTGAGAAAGCTTTCTCA GCCTTCTGGATCTCC). pBS/U6-siCRLF3 was a gift from Li Liu and used as a negative control (39) . The pBS/U6-siIFP35 plasmids were transfected into 293T or HeLa cells, and IFP35 expression was assayed by immunoblotting or fluorescence microscopy. Twenty-four hours after the siRNA transfection, BFV3026 was added to infect the cells, and FV replication was assessed 96 h later by enhanced-GFP (EGFP) expression through coculture with BICL cells.
EMSA. 293T cells were transfected with the empty vector, BTas alone, IFP35 alone, or BTas and IFP35. Two days later, the cells were lysed in 0.3 M NaCl for 30 min at 4°C, sonicated, and harvested by centrifugation at 14,000 ϫ g. The supernatants were then aliquoted and kept at Ϫ70°C. The BFV LTR was synthesized with the oligonucleotide BFV LTR (795 to 816) sense (5Ј-ATAGCTA TTTTAGTAAGTTAGC-3Ј). Position 1 is defined in this paper as the first nucleotide of the BFV proviral genome (GenBank accession no. AY 134750). Probes were purified, digitonin labeled, and used in electrophoretic mobility shift assays (EMSA) with a DIG gel shift kit (Roche).
RESULTS

Identification of IFP35 as a BTas-interacting protein.
BTas is composed of a DNA binding domain and the C-terminal transactivation domain (aa 184 to 249). To identify the potential proteins that interact with BTas, a yeast two-hybrid screening was performed with a human B-cell cDNA library and BTas (1-183aa) as the bait. Fifty positive clones were obtained from nutritional and colorimetric selections. Most of them were false positives, but one clone contained an in-frame 764-bp partial cDNA (GenBank accession no. NM 005533) which encodes amino acids 92 to 288 of the human IFP35 protein. IFP35 is an interferon-induced protein and may affect the function of BTas, so we chose IFP35 for further study.
To identify the specific binding region of BTas for IFP35, a series of Flag-BTas deletion mutants (Fig. 1A) were constructed and cotransfected with Myc-tagged IFP35. As shown in Fig. 1B , all of the C-terminally truncated mutants, including BTas (1-183aa) and BTas (1-217aa), retained the same ability to bind IFP35 as that of the wild-type protein. These results suggested that the IFP35 binding domain was not located in the activation domain (AD) (aa 184 to 249). The binding region was defined as BTas (133-183aa), since BTas (1-167aa) and BTas (⌬133-183aa) could not bind to IFP35 and BTas (⌬167-183aa) bound weakly, while BTas (167-249aa) and BTas (90-183aa) remained full binding ability ( Fig. 1C and D) . We also found that endogenous IFP35 coimmunoprecipitated with Myc-BTas in HeLa cells (Fig. 1E) . To map the BTas binding domain in IFP35, a series of Flag-IFP35 deletion mutants ( Fig.  2A ) were constructed and cotransfected with Myc-BTas. We found that IFP35 without its N-terminal leucine zipper domain retained the ability to bind to BTas, while IFP35 without NID2 did not (Fig. 2B) . Therefore, BTas-IFP35 complex formation is specific and depends on the presence of NID2.
The overexpression of IFP35 confers resistance to BFV infection in some cell types. BTas is an early regulatory protein and is required for the replication of BFV. It acts as a switch for BFV from latent to lytic replication (26) . Because IFP35 is an interferon-induced protein and can interact with BTas, we hypothesized that IFP35 might play a role in the replication of BFV. To test the possible antiviral effect of IFP35 against BFV infection, 293T cells were transfected with the empty vector or with IFP35 and then infected with BFV. Three days postinfection, viral antigen expression was monitored by immunofluorescence using an anti-Gag antibody. We found that the transfection of 293T cells with Myc-IP35 greatly decreased the level of Gag expression relative to that of control cells (Fig. 3A) . Similar results were obtained with BICL cells (data not shown).
To study the effects of IP35 overexpression on viral replication, 293T and HeLa cells were transfected with IFP35 or the empty vector and then infected with BFV. After 96 h, 1/20 of the cells were cocultured with BICL cells, which were then observed after 48, 72, and 96 h. As shown in Fig. 3B , overexpression of IFP35 in 293T cells was found to be associated with lower EGFP expression in BICL indicator cells. In contrast, overexpression of IFP35 did not inhibit the replication of BFV in HeLa cells (Fig. 3C ). Western blotting showed equal levels of IFP35 in the transfected cells (data not shown). In order to understand this discrepancy, we first tested the expression level of endogenous IFP35 in the two cell lines. Reverse transcription-PCR and Western blot assays showed that HeLa cells expressed a higher level of endogenous IFP35 than did 293T cells ( Fig. 3D and E ). Thus, it is possible that the level of endogenous IFP35 affects the replication of BFV. To test this, equal numbers of 293T and HeLa cells were infected with BFV, and total protein extracts 3 days after infection were analyzed by Western blotting using anti-Gag antibody. BFV infection did not induce syncytia in either HeLa or 293T cells. However, the viral titer in HeLa cells was significantly lower than that in 293T cells (Fig. 3F ). These results suggest that endogenous IFP35 could play an important role in inhibiting the replication of BFV in HeLa cells.
Intracellular localization of BFV BTas and IFP35. We next investigated the molecular mechanism involved in IFP35's inhibition of BFV replication. Using indirect immunofluorescence, BTas was found to accumulate predominantly in the nucleus, while IFP35 displayed a clear cytoplasmic distribution in HeLa cells (Fig. 4A ) and 293T cells (Fig. 4C ) cells when each was expressed alone. We next examined the localization of the two proteins when they were coexpressed. Interestingly, different results were seen for the two cell lines. In HeLa cells, there appeared to be high expression of BTas and IFP35 in both the nucleus and the cytoplasm (Fig. 4B) . In contrast, IFP35 relocalizes to the nucleus along with BTas in 293T cells (Fig. 4D) . These results suggest that the expression of BTas could induce a redistribution of IFP35 from the cytoplasm to the nucleus in 293T cells through a direct protein-protein in- teraction. This result may explain the discrepancy in results obtained with HeLa and 293T cells ( Fig. 3B and C) . IFP35 inhibits BTas-mediated BFV LTR transcriptional activation. BTas is a transactivator that functions in the nucleus. In 293T cells expressing BTas and IFP35, some IFP35 translocated from the cytoplasm to the nucleus, suggesting that the interaction between IFP35 and BTas may affect the function of BTas as the transactivator. In order to assess the role of IFP35 in the BTas-mediated transactivation of the BFV LTR, a luciferase reporter gene under the transcriptional control of the BFV LTR (LTR-luc) was used in transactivation experiments. 293T cells were transfected with both the BFV LTR-luc gene and the BTas gene in the presence or absence of IFP35. Luciferase levels were measured 48 h later (Fig. 5A) . Compared with control cells, IFP35 reduced the level of BTas-induced LTR transactivation and did so in a dose-dependent manner. With 500 ng of the IFP35 plasmid, the transactivation was inhibited by 64%. In control transfections without BTas, IFP35 had no effect on the very low level of basal promoter activity of LTR-luc. Western blotting showed equal levels of BTas in the transfected cells. Interestingly, the LTR transactivation in HeLa cells by BTas was not affected by IFP35, even with 500 ng of IFP35-expressing plasmid DNA (Fig. 5B) , consistent with the data in Fig. 3B . These results could be explained by the difference in relocalization of IFP35 in the presence of BTas in the two cell lines (Fig. 4) .
To identify the IFP35 domain(s) inhibiting BTas-driven transcription in 293T cells, similar experiments were performed with two IFP35 mutants, IFP35 (92-288aa) and IFP35 (1-170aa). Neither mutant was able to inhibit LTR transactivation (Fig. 5C ) suggesting that BTas is not inhibited by interacting with a simple domain of IFP35.
Knockdown of endogenous IFP35 by siRNA promotes BTasinduced BFV LTR activation. We have shown above that the overexpression of IFP35 has no inhibitory effect on the BTasinduced BFV LTR activation or replication of BFV in HeLa cells, which contain more endogenous IFP35 than do 293T cells. Thus, endogenous IFP35 may play an important role in the replication of FV. To examine this more closely, RNA interference analysis with IFP35-specific oligonucleotides was performed. First, pBS/U6-siIFP35 (encoding IFP35 siRNA), pBS/U6-siCRLF3 (encoding a control siRNA), and pBS/U6 (the empty vector) were each cotransfected with EGFP-IFP35 into 293T cells. Both fluorescence microscopy ( Fig. 6A) and Western blotting (Fig. 6B) showed that the expression of IFP35 was significantly reduced with pBS/U6-siIFP35 compared to that with the two controls. These results suggested that pBS/U6-siIFP35 could effectively inhibit the overex- pressed IFP35. The efficiency of pBS/U6-siIFP35 in depleting endogenous IFP35 was also examined in HeLa cells. The expression of IFP35 was significantly knocked down in the siIFP35-transfected HeLa cells, while transfection with either pBS/U6 or pBS/U6-siCRLF3 had no effect (Fig. 6C) . HeLa cells were transfected with BFV LTR-luc or a luc plasmid containing three copies of NF-B binding site [pNF-B (3ϫ)-luc] and BTas in the presence or absence of pBS/U6-siIFP35 plasmids to determine whether BFV LTR or NF-B activation would be enhanced by depleting endogenous IFP35. NF-B was examined because the BFV LTR contains an NF-B binding site and BTas can stimulate the NF-B pathway in HeLa cells. Luciferase assays showed that the induction of the BFV LTR promoter in the siIFP35-transfected cells increased but that BTas-induced NF-B activation was not affected (Fig.  6D) . These results suggest that the inhibition of IFP35 is specific to the BFV LTR and independent of the NF-B signal pathway. We next transfected HeLa cells with the pBS/U6-siIFP35, pBS/U6-siCRLF3, or pBS/U6 plasmid and then in- cells showed about a twofold increase in viral titer (Fig. 6E ), supporting the idea that endogenous IFP35 inhibits BFV replication in HeLa cells.
IFP35 does not inhibit the binding of BTas to the BFV LTR.
Our EMSA results showed that BTas can directly bind to the BFV LTR. Protein-protein interactions can result in the inhibition of the activity of either partner by preventing nuclear localization, DNA binding, or both. In order to determine whether IFP35 could affect the binding of BTas to BFV LTR, DNA binding studies were carried out with BTas binding sequences using extracts from cells expressing either the empty vector, BTas alone, IFP35 alone, or BTas and IFP35. We found that that a complex was formed in the extracts from cells transfected with BTas (Fig. 7A, lane 2) but not with the empty vector (Fig. 7A, lane 1) or with IFP35 alone (Fig. 7A, lane 3) . Coexpression of IFP35 and BTas did not alter the complex (Fig. 7A, lane 4) , and the complex could be removed by competition with an excess of unlabeled LTR DNA (Fig. 7A, lane  5) . As a positive control, we used purified BTas protein binding to the LTR (Fig. 7A, lane 6 ). This complex formation was found to be competed out with unlabeled LTR DNA (Fig. 7A,   lane 7) . Western blots using equal amounts of cell extract showed that all the cells expressed similar quantities of BTas and IFP35 (Fig. 7B) .
Although IFP35 did not inhibit the binding of BTas to the BFV LTR using the specific binding domain-containing oligonucleotide (aa 795 to 816), IFP35 could bind to another site on the full-length BFV LTR to interfere with BTas-induced transcription. To test this possibility, the GAL4 AD was fused to BTas (1-133aa) (the DNA binding domain of BTas) and to IFP35. GAL4 AD-IFP35 should be able to activate the transcription of the BFV LTR if IFP35 can bind directly to the BFV LTR. However, we found that neither the GAL4 AD (Fig. 7C, lane 1) , BTas (1-133aa) (Fig. 7C, lane 2) , IFP35 (Fig.  7C, lane 3) , nor GAL4 AD-IFP35 (Fig. 7C, lane 5) could activate the transcription of the BFV LTR in transfected 293T cells. In contrast, GAL4 AD-BTas (1-133aa) could strongly activate the transcription of the BFV LTR (Fig. 7C, lane 4) , because it binds to the BFV LTR. These results suggest that IFP35 cannot directly bind to the BFV LTR.
IFP35 inhibits Tas-induced PFV LTR activation. To determine whether our findings on the inhibition of Tas activity by IFP35 could be extended to other FVs, we examined whether Tas from PFV can interact with IFP35. At 48 h after cotransfection of 293T cells with Myc-tagged IFP35 and PFV Flagtagged Tas, cell extracts were immunoprecipitated using anti-Flag antibody. Precipitated proteins were resolved by SDS-polyacrylamide gel electrophoresis and analyzed by Western blotting using the anti-Myc and anti-Flag antibodies. Myc-IFP35 was observed to bind to Flag-Tas (Fig. 8A) . Similar data were obtained when the samples were immunoprecipitated with the anti-IFP35 antibody and analyzed by the anti-Flag antibody (Fig. 8A) . 293T cells were transfected with a luciferase reporter plasmid under the control of the PFV LTR and increasing amounts of IFP35, with or without Tas. Similarly to the results with BFV, IFP35 showed no effect on the basal promoter activity of LTR-luc, but it reduced PFV LTR transactivation by Tas in a dose-dependent manner (Fig. 8B) , with a decrease of 84% using 500 ng of IFP35-encoding plasmid.
DISCUSSION
In this paper, we have identified a physical interaction between the major BFV transactivator protein BTas and the cellular protein IFP35 by yeast two-hybrid screening. Coimmunoprecipitation experiments confirmed that an IFP35-BTas complex was formed in cells and that this interaction depends on the NID2 domain of IFP35 and the central domain of BTas. Prior to the current work, the only reported interferon-mediated FV inhibitor was PML (31) . However, the study by Meiering et al. (25) showed that endogenous PML does not limit the replication of PFV, suggesting that there might be other factors important for the interferon-mediated inhibition of FV replication. Our results suggest that IFP35 exerts an antiviral function by interfering with the transcription of viral genes via interaction with viral regulatory proteins. This may represent a novel antiviral pathway in the interferon action.
Some proteins that dimerize via their leucine zipper motif but lack a basic region for binding DNA have been found to be negative regulators of transcription (4) . It was suggested that IFP35 might be a negative transcriptional regulator, since it contains this kind of unique N-terminal leucine zipper motif (3). However, there is no experimental evidence that IFP35 perturbs gene transcription, even though IFP35 has been found to interact with two leucine zipper proteins, CKIP-1 and B-ATF (37, 40) . In this report, we show using transactivation assays with 293T cells that IFP35 can reduce BTas-dependent activation of the BFV LTR in a dose-dependent manner. This inhibition requires both NID2, which is necessary for the formation of an IFP35-BTas complex, and the N-terminal leucine zipper motif. This result provides evidence for the idea that the N-terminal leucine zipper motif of IFP35 is a negative regulator of transcription. In addition, our EMSA results show that IFP35 neither directly binds to the BFV LTR nor inhibits the (10) can receive an activating signal in the cytoplasm and rapidly shuttle into the nucleus. Other diverse transcription factor families, including the interferon regulatory factor (IRF) (32), the signal transducer and activator of transcription (STAT) (7), the NF-B (15, 16) , and the nuclear factor of activated T cells (NFAT) (6) families, can also respond to the external signals in the same way. The functional diversity of such transcription factors depends upon modifications (such as phosphorylation) and/or interactions with other transcription factors that are coexpressed and/or activated in the infected cells (34, 36) . In this study, we observed a cytoplasm-to-nucleus translocation of IFP35 when it was coexpressed with BTas. A similar cytoplasm-to-nucleus translocation of IFP35 was reported when IFP35 was induced by the interferon treatment (3). We believe that this redistribution is necessary for the biological function of IFP35. Our results suggest that BTas could act as a chaperone for the nuclear entry of IFP35 by direct interaction.
The different inhibitory effects of IFP35 on BFV in HeLa and 293T cells may be caused by the level of endogenous IFP35, which is at a higher level in HeLa cells than in 293T cells (3, 5) . We believe that endogenous IFP35 plays a more important role in inhibiting BFV in HeLa cells than in 293T cells. This idea is supported by the increase in BFV LTRdriven activation after the repression of endogenous IFP35 by RNAi. Thus, endogenous IFP35 might account for the low activation of BFV in HeLa cells. In addition, very little IFP35 entered the nucleus when BTas and IFP35 were cotransfected into HeLa cells, which is different from the results with 293T cells. Coupled with the high level of endogenous IFP35, this may explain why overexpressed IFP35 did not inhibit BFV replication in HeLa cells.
Most retroviruses cause disease after infecting natural or accidental hosts. The genomic organization of FVs shows striking similarity to those of other retroviruses, especially human T-cell leukemia virus type I and human immunodeficiency virus type 1. In addition, FVs share many characteristics with the human pathogen hepatitis B virus, such as reverse transcription late in infection, leading to a DNA genome (23) . However, no specific disease related to FVs has been reported (23) . Understanding the mechanisms responsible for latent infection induced by FV may yield insight into pathogenesis by other retroviruses. It may also aid in the development of FVs as vectors for gene therapy. In this study, although most the experiments were done in a heterologous system (bovine FV Tas and human IFP35), the Tas-mediated transactivation of either BFV or PFV could be significantly reduced when enough IFP35 was present. Our data suggest that IFP35 could be a general mechanism for inhibiting FV replication.
